natgillin/translations-raw huggingface dataset:
In a second field study involving 294 cats with hypertension with average age 13 years, 194 cats given Semintra once a day for 28 days had a reduction of SBP of 25 mmHg at day 28 compared to 11 mmHg for 100 cats given placebo (a dummy treatment). 
V drugi terenski študiji, ki je vključevala 294 mačk s hipertenzijo, starih povprečno 13 let, se je sistolični krvni tlak po 28 dneh pri 194 mačkah, ki so prejemale zdravilo Semintra enkrat na dan 28 dni, znižal za 25 mmHg, pri 100 mačkah, ki so prejemale placebo (zdravilo brez zdravilne učinkovine), pa se je znižal za 11 mmHg.
In a field study involving 224 cats with chronic kidney disease, aged mainly over 11 years, Semintra was as effective as benazepril, another veterinary medicine used to reduce proteinuria, in reducing proteinuria. 
V terenski študiji, ki je vključevala 224 mačk s kronično ledvično boleznijo, večinoma starih več kot 11 let, je bilo zdravilo Semintra pri zniževanju proteinurije enako učinkovito kot benazepril, drugo
At the end of the 28 days Semintra treated cats continued to be treated for an additional 92 days and these cats had a reduction of SBP of more than 20 mmHg for the entire 4 month study period. 
Po koncu 28-dnevnega obdobja so se mačke, zdravljene z zdravilom Semintra, zdravile še dodatnih 92 dni, sistolični krvni tlak pa se jim je v celotnem štirimesečnem obdobju študije znižal za več kot 20 mmHg.
Semintra must not be given to pregnant or lactating cats. 
Zdravilo Semintra se ne sme uporabljati pri brejih mačkah ali mačkah v obdobju laktacije.
By blocking the receptor to which angiotensin II normally attaches, telmisartan stops the hormone having an effect, allowing the blood vessels to expand. 
Telmisartan z zaviranjem receptorja, na katerega se angiotenzin II običajno veže, prepreči učinek hormona, kar privede do razširitve žil.
Semintra is available as a solution to be given by mouth and can only be obtained with a veterinary prescription. 
Zdravilo Semintra je na voljo v obliki raztopine, ki se daje peroralno, njegovo predpisovanje in izdaja pa je le na veterinarski recept.
How is Semintra used? 
Kako se zdravilo Semintra uporablja?
How does Semintra work? 
Kako zdravilo Semintra deluje?
Date of first authorisation: 19 November 2007 Date of latest renewal: 19 November 2012 
Datum prve odobritve: 19. november 2007 Datum zadnjega podaljšanja: 19. november 2012
This study is ongoing. 
Študija še poteka.
(Best response rate) 
(največji delež odzivov)
**Also includes preferred term anorexia 
**vključuje tudi bolj uporabljen izraz anoreksija
These changes are unlikely to be clinically important. 
Te spremembe po vsej verjetnosti niso klinično pomembne.
- Risk Management Plan (RMP) 
• Načrt za obvladovanje tveganj (RMP)
Unexpected, rapid weight gain should be carefully investigated. 
Nepričakovan, hiter porast teže je treba temeljito raziskati.
Interaction studies have only been performed in adults. 
Interakcijske študije so izvajali samo pri odraslih.
Sudden death 
Nenadna smrt
This is a long-term treatment. 
Gre za dolgotrajno zdravljenje.
The presence of hypokalaemia and hypomagnesaemia may further enhance this effect. 
Hipokaliemija in hipomagneziemija lahko še dodatno okrepita ta učinek.
This medicine contains lactose (also known as milk sugar). 
To zdravilo vsebuje laktozo (znano tudi kot mlečni sladkor).
Rifampicin and nilotinib should not be used concomitantly. 
Rifampicina in nilotiniba se ne sme uporabljati sočasno.
Tasigna blocks this signal, and thus stops the production of these cells. 
Zdravilo Tasigna ovira ta signal in tako ustavi izdelovanje teh celic.
- Do not open the hard capsules unless you are unable to swallow them. 
- Trdih kapsul ne odpirajte razen, če jih ne morete pogoltniti.
The total daily dose you give to your child must not exceed 800 mg. 
Celotni dnevni odmerek, ki ga dajete otroku, ne sme presegati 800 mg.
Some children and adolescents taking Tasigna may have slower than normal growth. 
Pri nekaterih otrocih in mladostnikih, ki jemljejo zdravilo Tasigna, je rast lahko počasnejša kot normalno.
Accelerated phase 
Pospešena faza
Do not drink grapefruit juice or eat grapefruit. 
Ne pijte grenivkinega soka in ne jejte grenivk.
Months since randomisation 
meseci po randomizaciji
60-month analysis 
60 mesečna analiza
Follow all the doctor's instructions carefully. 
Skrbno se ravnajte po vseh navodilih vašega zdravnika.
The doctor will calculate the correct dose to use and tell you which and how many capsules of Tasigna to give to your child. 
Zdravnik bo izračunal pravi odmerek za uporabo in vam povedal, katere in koliko kapsul zdravila Tasigna boste dajali otroku.
Use in children and adolescents - The dose given to your child will depend on your child's body weight and height. 
Uporaba pri otrocih in mladostnikih - Odmerek, ki ga bo prejemal vaš otrok, bo odvisen od njegove telesne mase in telesne višine.
Time since TFR (weeks) 
čas od TFR (tedni)
More than 60% of all patients were Caucasian and 25% of all patients were Asian. 
Več kot 60 % vseh bolnikov je bilo belcev, 25 % vseh bolnikov pa je bilo azijcev.
Investigations Very common: 
Preiskave zelo pogosti:
They may differ from the general information contained in this leaflet. 
Morda se ta razlikujejo od splošnih navodil v tem navodilu za uporabo.
Do not take Tasigna - if you are allergic to nilotinib or any of the other ingredients of this medicine (listed in section 6). 
Ne jemljite zdravila Tasigna - če ste alergični na nilotinib ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Take the hard capsules: - twice a day (approximately every 12 hours); - at least 2 hours after any food; - then wait 1 hour before eating again. 
Trdi kapsuli vzemite: - dvakrat na dan (približno vsakih 12 ur); - vsaj 2 uri po uživanju kakršnekoli hrane; - nato počakajte vsaj 1 uro, preden spet jeste.
More frequent follow-up of these patients should be considered. 
Pri teh bolnikih velja razmisliti o pogostejših kontrolnih pregledih.
Approximately 12% of subjects in the clinical study were 65 years of age or over. 
Približno12 % oseb v klinični študiji je bilo starih 65 let ali več.
Bioavailability/bioequivalence studies 
Študije biološke uporabnosti/bioekvivalentnosti
Molecular relapse can occur during the treatment-free phase, and long-term outcome data are not yet available. 
V obdobju brez zdravljenja lahko pride do molekularnega relapsa, podatki o dolgoročnih izidih pa še niso na voljo.
In general the changes in clinical chemistry were fully reversible after a four-week recovery period and the histological alterations showed partial reversibility. 
Na splošno so bile spremembe s področja klinične kemije popolnoma reverzibilne v 4-tedenskem obdobju okrevanja, histološke spremembe pa so bile le deloma reverzibilne.
- the level of sugar and fats in the blood. 
- vrednosti sladkorja in maščob v krvi.
Taking Tasigna at the same time each day will help you remember when to take your hard capsules. 
Če boste jemali zdravilo Tasigna vsak dan ob istem času, si boste najlaže zapomnili, kdaj morate vzeti trdi kapsuli.
Unchanged nilotinib accounted for 69% of the dose. 
Nespremenjeni nilotinib je znašal 69 % odmerka.
Most of the side effects are mild to moderate and will generally disappear after a few days to a few weeks of treatment. 
Večina neželenih učinkov je blagih do zmernih in večinoma izzvenijo po nekaj dneh do nekaj tednih zdravljenja.
Your doctor will regularly monitor your condition to check that the treatment is having the desired effect. 
Vaš zdravnik bo redno spremljal vaše stanje in preverjal, ali zdravljenje dosega želeni učinek.
Tasigna is available in the following pack sizes: 
Zdravilo Tasigna je na voljo v naslednjih velikostih pakiranj:
Tasigna has no or negligible influence on the ability to drive and use machines. 
Tasigna nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Dose adjustments or modifications 
Prilagoditve in modifikacije odmerkov
If a dose is missed the patient should not take an additional dose, but take the usual prescribed next dose. 
Če bolnik pozabi vzeti odmerek, ne sme vzeti dodatnega odmerka, ampak naj vzame naslednji običajni predpisani odmerek.
Pregnancy and breast-feeding - Tasigna is not recommended during pregnancy unless clearly necessary. 
Nosečnost in dojenje - Uporaba zdravila Tasigna med nosečnostjo ni priporočena, če to ni nujno potrebno.
Metabolism and nutrition disorders Decreased appetite ** 
Presnovne in prehranske motnje zmanjšan apetit**
If you think you may be allergic, tell your doctor before taking Tasigna. 
Če mislite, da bi bili lahko alergični, povejte svojemu zdravniku preden vzamete zdravilo Tasigna.
The AUC of imatinib was increased by 18% to 39%, and the AUC of nilotinib was increased by 18% to 40%. 
AUC imatiniba se je povečala za 18 % do 39 %, AUC nilotiniba pa za 18 % do 40 %.
Treatment should be continued as long as clinical benefit is observed or until unacceptable toxicity occurs. 
Zdravljenje je treba nadaljevati, dokler je pri bolniku mogoče opaziti klinične koristi oziroma do pojava nesprejemljive toksičnosti.
Stopping Tasigna without your doctor's recommendation places you at risk for worsening of your disease which could have life-threatening consequences. 
Če prenehate jemati zdravilo Tasigna brez zdravnikovega priporočila, tvegate poslabšanje bolezni, kar lahko ima življenjsko ogrožujoče posledice.
These adverse reactions are included based on clinical relevance. 
Ti neželeni učinki so vključeni na podlagi kliničnega pomena.
These medicines should be avoided during your treatment with Tasigna. 
Tem zdravilom se je treba med zdravljenjem z zdravilom Tasigna izogibati.
Table 12 Response in CML 
Preglednica 12 Odzivi pri KML
Similar events were observed in post-marketing reports. 
O podobnih dogodkih so poročali tudi v obdobju trženja zdravila.
In addition, the toxicity profile in juvenile rats was comparable to that observed in adult rats. 
Poleg tega je bil tudi profil toksičnosti pri mladičih primerljiv s tistim, ki so ga opažali pri odraslih živalih.
Main metabolic pathways identified in healthy subjects are oxidation and hydroxylation. 
Poglavitna presnovna procesa, ki so ju ugotovili pri zdravih osebah, sta oksidacija in hidroksilacija.
Prolongation of the QT interval or an irregular heart beat may lead to sudden death. 
Podaljšanje intervala QT ali nepravilno bitje srca lahko vodita v nenadno smrt.
Your doctor may prescribe a lower dose depending on how you respond to treatment. 
Zdravnik vam bo morda predpisal nižji odmerek glede na vaš odziv na zdravljenje.
Tasigna must not be taken in conjunction with food (see sections 4.2 and 4.5) and should be taken 2 hours after a meal. 
Zdravila Tasigna se ne sme jemati skupaj s hrano (glejte poglavji 4.2 in 4.5), ampak ga je treba vzeti 2 uri po obroku.
In the event of overdose, the patient should be observed and appropriate supportive treatment given. 
V primeru zaužitja prevelikega odmerka je treba bolnika opazovati in poskrbeti za ustrezno podporno zdravljenje.
Anti-arrhythmic medicinal products and other substances that may prolong the QT interval 
Antiaritmiki in druge snovi, ki lahko podaljšujejo interval QT
What Tasigna is and what it is used for 
Kaj je zdravilo Tasigna in za kaj ga uporabljamo
Randomisation was stratified by Sokal risk score at the time of diagnosis. 
Randomizacija je bila stratificirana glede na oceno tveganja po Sokalu v času postavitve diagnoze.
What you need to know before you take Tasigna 
Kaj morate vedeti, preden boste vzeli zdravilo Tasigna
The doctor will monitor growth at regular visits. 
Zdravnik bo pri rednih pregledih spremljal rast otroka.
Therefore the risk that nilotinib causes photosensitisation in patients is considered very low. 
Zato je tveganje, da bi nilotinib povzročal fotosenzitivnost, ocenjeno za zelo nizko.
Growth retardation in paediatric population 
Zastoj rasti pri pediatrični populaciji
Medical treatment may be necessary. 
Morda boste potrebovali zdravniško pomoč.
The primary data analysis time point was when all 846 patients completed 12 months of treatment (or discontinued earlier). 
Vnaprej opredeljena časovna točka primarne analize podatkov je bila takrat, ko je vseh 846 bolnikov zaključilo 12 mesecev zdravljenja (oziroma so predhodno prenehali s sodelovanjem).
Among these 88 patients, 86 patients restarted nilotinib treatment and 2 patients permanently discontinued the study. 
Med temi 88 bolniki jih je 86 ponovno začelo prejemati nilotinib, 2 bolnika pa sta dokončno prekinila sodelovanje v študiji.
Tasigna hard capsules contain lactose. 
Trde kapsule Tasigna vsebujejo laktozo.
Prolongation of the QT interval may expose patients to the risk of fatal outcome. 
Podaljšanje intervala QT lahko za bolnika pomeni izpostavljenost smrtni nevarnosti.
If it is used during pregnancy, the patient must be informed of the potential risk to the foetus. 
V primeru, da ga bolnica uporablja med nosečnostjo, mora biti seznanjena z možnimi tveganji za plod.
Patients should be advised to seek immediate medical attention if they experience acute signs or symptoms of cardiovascular events. 
Bolnike je treba podučiti, da v primeru pojava akutnih znakov ali simptomov srčnožilnih dogodkov takoj poiščejo zdravniško pomoč.
The median time on treatment was approximately 70 months in the nilotinib treatment groups and 64 months in the imatinib group. 
Mediana trajanja zdravljenja je bila približno 70 mesecev v skupini z nilotinibom in 64 mesecev v skupini z imatinibom.
- Do not use this medicine after the expiry date which is stated on the carton and blister. 
- Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu.
Continue taking Tasigna every day for as long as your doctor tells you. 
Zdravilo Tasigna jemljite vsak dan in nadaljujte, dokler vam tako svetuje zdravnik.
Since a risk to the newborns/infants cannot be excluded, women should not breast-feed during Tasigna treatment and for 2 weeks after the last dose. 
Ker tveganja za dojenega novorojenca/otroka ne moremo izključiti, ženske v času zdravljenja z zdravilom Tasigna in še 2 tedna po prejemu zadnjega odmerka ne smejo dojiti.
If you have any questions about how Tasigna works or why it has been prescribed for you or your child, ask your doctor. 
Če imate kakšna vprašanja glede tega, kako zdravilo Tasigna deluje ali zakaj so ga predpisali vam oziroma vašemu otroku, vprašajte svojega zdravnika.
If any of these apply to you or your child, tell your doctor. 
Če karkoli od zgoraj navedenega velja za vas ali vašega otroka, povejte svojemu zdravniku.
Safety information from two Tasigna treatment discontinuation studies is also provided. 
Navedeni so tudi varnostni podatki iz dveh študij prekinitve zdravljenja z zdravilom Tasigna.
It is unknown whether nilotinib is excreted in human milk. 
Ni znano, ali se nilotinib izloča v materino mleko.
If you are taking any of these, your doctor might prescribe other alternative medicines. 
Če jemljete katero od teh zdravil, vam bo zdravnik morda predpisal drugo ustrezno zdravilo.
Steady-state conditions were essentially achieved by day 8. 
Do stanja dinamičnega ravnovesja je v glavnem prišlo do 8. dne.
No major differences were observed for safety and efficacy in patients ≥65 years of age as compared to adults aged 18 to 65 years. 
Pri bolnikih, starih 65 let ali več, niso opažali večjih razlik glede varnosti in učinkovitosti v primerjavi z odraslimi, starimi 18 do 65 let.
Overall, 73% of patients were imatinib-resistant, while 27% were imatinib-intolerant. 
Skupno je bilo 73 % bolnikov rezistentnih na imatinib, 27 % pa jih ni prenašalo imatiniba.
Contains lactose - see the package leaflet for further information. 
Vsebuje laktozo - za več podatkov glejte Navodilo za uporabo.
The hard capsules should be swallowed whole with water. 
Trde kapsule je treba pogoltniti cele z vodo.
The blood-to-plasma ratio of nilotinib is 0.71. 
Razmerje vsebnosti kri/plazma je pri nilotinibu 0,71.
Eligibility for discontinuation of treatment 
Primernost za prekinitev zdravljenja
You should also tell your doctor if you are already taking Tasigna and you are prescribed a new medicine that you have not taken previously during Tasigna treatment. 
Zdravniku morate povedati tudi v primeru, da že jemljete zdravilo Tasigna, pa vam predpišejo novo zdravilo, ki ga prej med zdravljenjem z zdravilom Tasigna še niste jemali.
Since nilotinib and its metabolites are not renally excreted, a decrease in total body clearance is not anticipated in patients with renal impairment. 
Ker se nilotinib in njegovi metaboliti ne izločajo preko ledvic, pri bolnikih z okvaro ledvic ni pričakovati znižanja celotnega telesnega očistka.
Genotoxicity studies in bacterial in vitro systems and in mammalian in vitro and in vivo systems with and without metabolic activation did not reveal any evidence for a mutagenic potential of nilotinib. 
Študije genotoksičnosti na bakterijskih sistemih in vitro ter na sesalskih sistemih in vitro in in vivo, z metabolično aktivacijo ali brez nje, niso dale nobenega dokaza za mutageni potencial nilotiniba.
However, it is recommended that patients experiencing dizziness, fatigue, visual impairment or other undesirable effects with a potential impact on the ability to drive or use machines safely should refrain from these activities as long as the undesirable effects persist (see section 4.8). 
Kljub temu velja priporočilo, da bolniki, pri katerih prihaja do omotičnosti, utrujenosti, motenj vida ali drugih neželenih učinkov, ki bi lahko vplivali na sposobnost varne vožnje ali upravljanja s stroji, ne smejo opravljati teh dejavnosti, dokler neželeni učinki vztrajajo (glejte poglavje 4.8).
CML is a cancer of the blood which makes the body produce too many abnormal white blood cells. 
KML je krvni rak, zaradi katerega telo izdeluje preveč nenormalnih levkocitov.
If transient interruption of treatment is not possible, close monitoring of the individual for prolongation of the QT interval is indicated (see sections 4.2, 4.5 and 5.2). 
Če začasna prekinitev zdravljenja ni možna, je treba posameznika natančno spremljati glede podaljšanja intervala QT (glejte poglavja 4.2, 4.5 in 5.2).
No effects were seen in ECG measurements in dogs or monkeys treated for up to 39 weeks or in a special telemetry study in dogs. 
Vpliva na meritve EKG niso opažali niti pri psih niti pri opicah, ki so jih z nilotinibom zdravili do 39 tednov, niti v posebni telemetrični študiji na psih.
Tasigna should not be used during pregnancy unless the clinical condition of the woman requires treatment with nilotinib. 
Zdravila Tasigna ne smete uporabljati med nosečnostjo, razen če je zdravljenje z nilotinibom potrebno zaradi kliničnega stanja ženske.
How to take Tasigna - Swallow the hard capsules whole with water. 
Kako jemati zdravilo Tasigna - Trde kapsule pogoltnite cele z vodo.
No deaths were reported on treatment or after treatment discontinuation in both studies. 
V nobeni od obeh študij niso poročali o primerih smrti niti v času zdravljenja niti po njegovi prekinitvi.
The hard capsules are red. 
Trde kapsule so rdeče.
Subsequent analyses reflect when patients completed 24, 36, 48, 60 and 72 months of treatment (or discontinued earlier). 
Nadaljnje analize vključujejo podatke bolnikov po zaključenih 24, 36, 48, 60 in 72 mesecih zdravljenja (oziroma tistih, ki so predhodno prenehali s sodelovanjem).
The following adverse reactions have been derived from post-marketing experience with Tasigna via spontaneous case reports, literature cases, expanded access programmes, and clinical studies other than the global registration trials. 
Naslednji neželeni učinki so pridobljeni iz izkušenj v obdobju trženja zdravila Tasigna, in sicer s spontano sporočenimi primeri, iz literaturnih podatkov, iz programov razširjene uporabe in kliničnih študij, drugih kot v okviru globalnih preskušanj za registracijo zdravila.
If clinically significant moderate or severe non-haematological toxicity develops, dosing should be interrupted, and patients should be monitored and treated accordingly. 
Če pride do klinično pomembne zmerne ali hude nehematološke toksičnosti, je treba odmerjanje prekiniti in bolnika ustrezno spremljati in zdraviti.
As compared to an oral drink solution (pH of 1.2 to 1.3), relative bioavailability of nilotinib capsule is approximately 50%. 
V primerjavi s pitjem peroralne raztopine (z vrednostjo pH od 1,2 do 1,3) je relativna biološka uporabnost nilotiniba iz kapsul približno 50 %.
Food may enhance the absorption of Tasigna and therefore increase the amount of Tasigna in the blood, possibly to a harmful level. 
Hrana lahko poveča absorpcijo zdravila Tasigna in tako poveča količino zdravila Tasigna v krvi, lahko tudi toliko, da postane škodljivo.
If you are pregnant or think that you may be, tell your doctor who will discuss with you whether you can take this medicine during your pregnancy. 
Če ste noseči ali domnevate, da bi lahko bili, povejte zdravniku, da se bo z vami pogovoril o tem, ali lahko jemljete to zdravilo med nosečnostjo.
The apparent elimination half-life estimated from the multiple-dose pharmacokinetics with daily dosing was approximately 17 hours. 
Navidezni razpolovni čas izločanja, ocenjen na podlagi farmakokinetike večkratnih odmerkov pri odmerjanju enkrat dnevno, je bil približno 17 ur.
2 Very common 
2 zelo pogosti
These are important in the functioning of the heart. 
Ti elektroliti so pomembni za delovanje srca.
Forty patients (58.0%) had relative dose intensity superior to 90%. 
Štirideset bolnikov (58,0 %) je prejelo zdravljenje z relativno jakostjo odmerjanja več kot 90 %.
(0.0032% IS < BCR-ABL/ABL ≤0.01% IS). 
(0,0032 % po IS < BCR-ABL/ABL ≤0,01 % po IS).
Not all packs may be marketed in your country. 
V vaši državi na trgu morda ni vseh navedenih pakiranj.
Do not use more than one teaspoon of apple sauce for each hard capsule and do not use any food other than apple sauce. 
Pri tem ne smete uporabiti več kot ene čajne žličke jabolčnega soka za vsako trdo kapsulo in nobenega drugega živila, ki ni jabolčni sok.
If event occurs after dose reduction, consider discontinuing treatment. 
Če do dogodka pride po znižanju odmerka, je treba razmisliti o dokončni ukinitvi odmerjanja.
The median highest prior imatinib dose had been 600 mg/day. 
Mediana najvišjega predhodnega odmerka imatiniba je bila 600 mg/dan.
Up to 0.32 m 
do 0,32 m
Reactivation of hepatitis B in patients who are chronic carriers of this virus has occurred after these patients received BCR-ABL tyrosine kinase inhibitors. 
Reaktivacija hepatitisa B pri bolnikih, ki so kronični prenašalci tega virusa, se je pojavila, potem ko so ti bolniki prejeli zaviralce BCR-ABL tirozin-kinaze.
Tasigna was administered on a continuous basis (twice daily 2 hours after a meal and with no food for at least one hour after administration) unless there was evidence of inadequate response or disease progression. 
Zdravilo Tasigna so bolniki prejemali neprekinjeno (dvakrat dnevno 2 uri po obroku, po aplikaciji zdravila pa vsaj eno uro niso uživali hrane), razen če so odkrili nezadosten odziv ali napredovanje bolezni.
Therapy should be initiated by a physician experienced in the diagnosis and the treatment of patients with CML. 
Zdravljenje mora začeti zdravnik, izkušen v diagnostiki in zdravljenju bolnikov s KML.
In paediatric patients, treatment must be interrupted until the event returns to Grade 1. 
Pri pediatričnih bolnikih je treba zdravljenje prekiniti, dokler se vrednosti ne znižajo do stopnje 1.
Do not stop taking this medicine unless your doctor tells you to do so. 
Ne prenehajte jemati tega zdravila, če vam tega ni naročil zdravnik.
Since these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to nilotinib exposure. 
Ker so o teh neželenih učinkih poročali spontano pri bolnikih iz populacij nedoločljive velikosti, ni vedno mogoče zanesljivo določiti pogostnosti teh neželenih učinkov oziroma ugotoviti njihove vzročne povezave z izpostavljenostjo nilotinibu.
Carcinogenicity studies 
Študije karcinogenosti